- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02086058
Gene Expression in the Overactive Bladder in Children
Gene Expression in the Bladder in Children With an Overactive Bladder and Daytime Urinary Incontinence
The aim of this study (the hypothesis) is to identify differences in the gene expression profile in the bladder muscle and hereby gain greater knowledge about the muscular mechanisms that cause overactive bladder and daytime urinary incontinence in children older than 5 years. A secondary aim is to examine how this gene expression profile differs from children with a neurogenic overactive bladder and how the gene expression profile changes from childhood till adulthood. Such new knowledge will result in a more precisely targeted and hence effective treatment of overactive bladder.
The results will be obtained by retrieving bladder biopsies from children and adults suffering from an overactive bladder or a neurogenic bladder. These biopsies will undergo molecular analysis and the investigators will compare them with biopises from bladder healthy adults and children.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
Aarhus N
-
Aarhus, Aarhus N, Danemark, 8200
- Recrutement
- Center for child incontinence, Aarhus University hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
Group 1: Group 1 (non-neurogenic bladder/overactive bladder):
- age 5-14 years of age
- patients must have filled out 48-hour bladder diaries
- a minimum of 4 micturitions per day (assessed from the bladder diaries)
- functional daytime urinary incontinence
- overactive bladder as defined by urgency
- no signs of neurogenic bladder dysfunction on invasive urodynamics
- a non-remarkable clinical examination
- normal BMI (between 3-97 percentile)
- informed oral and written consent from the child and both parents/legal guardian. In the informed consent the parents /legal guardian have given permission to the authorities (The Danish Ethical Committee), so that they may get information about the child during monitoring and quality inspection visits.
- no effect of prior treatment of at least 6 months urotherapy
- no effect of prior treatment of at least 3 months of anticholinergic treatment
- planned to undergo a cystoscopy under anesthesia
Group 2:
- 5-14 years of age or >18 years old
- diagnosed with a neurogenic bladder (i.e. caused by myelomeningocele)
- informed oral and written consent from the child and both parents/legal guardian. In the informed consent the parents /legal guardian have given permission to the authorities (The Danish Ethical Committee), so that they may get information about the child during monitoring and quality inspection visits.
- planned to undergo a cystoscopy under anesthesia
Group 3:
- age 5-14 years of age or >18 years old
- a non-remarkable clinical examination
- a normal voiding pattern
- a minimum of 3 micturitions per day
- planned to undergo a cystoscopy under anesthesia
Exclusion Criteria:
Group 1:
- Neurological and/or anatomical abnormalities in the lower urinary tract
- a medical history, clinical or biochemical tests that indicate that the child suffers from any type of disease (such as acute urinary infection or diabetes) or condition (such as pregnancy) influencing the child´s possibility of participating in the study, or that may effect the study parameters that are under examination.
- ongoing fecal problems such as fecal incontinence or constipation
- prior surgery involving the bladder
- ongoing urinary tract infections
- ongoing treatment with any type of medicine that may effect the study parameters that are under examination
Group 2:
- a medical history, clinical or biochemical tests that indicate that the child suffers from any type of diseases (such as diabetes) or conditions (such as pregnancy) influencing the child´s possibility of participating in the study, or that may affect the study parameters that are under examination.
- ongoing treatment with any type of medicine that may affect the study parameters that are under examination
Group 3:
- Neurological and/or anatomical abnormalities in the lower urinary tract
- urinary incontinence and an overactive bladder with urinary incontinence
- a medical history, clinical or biochemical tests that indicate that the patient suffers from any type of disease (such as acute urinary tract infection or diabetes) or condition (such as pregnancy) influencing the patient´s possibility of participating in the study, or that may effect the study parameters that are under examination.
- any type of bladder disease or any disease secondary affecting the bladder
- prior bladder surgery
- ongoing urinary tract infection
- ongoing treatment with any type of medicine that may effect the study parameters that are under examination.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Up- and down regulation of genes expressed in the bladder
Délai: collection of bladder material and analysis will take approximately 2 years
|
We will evaluate the gene expression (which genes are up- and/or down regulated) in the bladder in healthy children compared to children suffering from an overactive bladder.
This gene expression will then be compared to the gene expression in bladder tissue from adults, to evaluate what happens in the bladder from childhood to adulthood.
|
collection of bladder material and analysis will take approximately 2 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Luise Borch, M.D, University of Aarhus
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GeneOAB
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .